S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
NASDAQ:ACIU

AC Immune (ACIU) Stock Price, News & Analysis

$2.74
+0.01 (+0.37%)
(As of 04/12/2024 ET)
Today's Range
$2.69
$2.77
50-Day Range
$2.66
$3.95
52-Week Range
$1.78
$5.14
Volume
39,028 shs
Average Volume
162,551 shs
Market Capitalization
$270.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

AC Immune MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
483.9% Upside
$16.00 Price Target
Short Interest
Healthy
0.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.26mentions of AC Immune in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.75) to ($0.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.68 out of 5 stars

Medical Sector

1318th out of 2,784 stocks

Pharmaceutical Preparations Industry

607th out of 1,293 stocks

ACIU stock logo

About AC Immune Stock (NASDAQ:ACIU)

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

ACIU Stock Price History

ACIU Stock News Headlines

AC Immune S.A.
Buy Alert: Get these AI trades on repeat
With this AI Trade Finder, one of my newer students took his trading account from $1,500 to over $9,400 in just over a month
ACIU Mar 2024 2.500 put
Buy Alert: Get these AI trades on repeat
With this AI Trade Finder, one of my newer students took his trading account from $1,500 to over $9,400 in just over a month
5 Little-Known Penny Stocks With Massive Upside Potential
ACIU May 2024 2.500 call
ACIU Aug 2024 2.500 call
AC Immune Ltd (ACIU)
5 Small-Cap Stocks to Play the January Effect
AC Immune (ACIU) Upgraded to Buy: Here's Why
See More Headlines
Receive ACIU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
4/12/2024
Next Earnings (Estimated)
4/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACIU
Employees
133
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$16.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+486.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-60,410,000.00
Pretax Margin
-366.34%

Debt

Sales & Book Value

Annual Sales
$16.48 million
Book Value
$2.12 per share

Miscellaneous

Free Float
94,350,000
Market Cap
$270.00 million
Optionable
Optionable
Beta
1.00
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Andrea Pfeifer Ph.D. (Age 67)
    Co-Founder, CEO & Director
    Comp: $1.12M
  • Mr. Christopher Roberts (Age 34)
    CFO & VP of Finance
  • Mr. Piergiorgio Donati (Age 53)
    Chief Technical Operations Officer
  • Mr. Jean-Fabien Monin (Age 53)
    Chief Administrative Officer
  • Mr. Howard Donovan (Age 48)
    Chief HR Officer
  • Ms. Madiha Derouazi (Age 51)
    Chief Scientific Officer
  • Dr. Gary Anthony Waanders Ph.D. (Age 60)
    Senior VP of Investor Relations & Corporate Communications
  • Mr. Alexandre Caratsch (Age 58)
    General Counsel
  • Mr. Julian Snow
    VP of U.S. Finance & Corporate Development
  • Dr. David T. Hickman
    Head of AD - SME

ACIU Stock Analysis - Frequently Asked Questions

Should I buy or sell AC Immune stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACIU shares.
View ACIU analyst ratings
or view top-rated stocks.

What is AC Immune's stock price target for 2024?

1 equities research analysts have issued 12 month price targets for AC Immune's shares. Their ACIU share price targets range from $16.00 to $16.00. On average, they expect the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 483.9% from the stock's current price.
View analysts price targets for ACIU
or view top-rated stocks among Wall Street analysts.

How have ACIU shares performed in 2024?

AC Immune's stock was trading at $5.00 at the beginning of 2024. Since then, ACIU stock has decreased by 45.2% and is now trading at $2.74.
View the best growth stocks for 2024 here
.

When is AC Immune's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024.
View our ACIU earnings forecast
.

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) released its quarterly earnings results on Thursday, March, 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The business earned $16.71 million during the quarter, compared to analyst estimates of $16.36 million.

What is Andrea Pfeifer's approval rating as AC Immune's CEO?

3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AC Immune own?
When did AC Immune IPO?

AC Immune (ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

How do I buy shares of AC Immune?

Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACIU) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners